DMSO-treated HL60 cells: A model of neutrophil-like cells mainly expressing PDE4B subtype

International Immunopharmacology

Volumn 2, Issue 12, 2002, Pages 1647-1656

  Jacob, C ^a   Leport, M ^a   Szilagyi, C ^a   Allen, J M ^a   Bertrand, C ^a   Lagente, V ^b  

^a PFIZER INC   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Cellular model; Differentiated HL60 cells; Neutrophilic phenotype; PDE4A down regulation linked to NADPH oxidase activity; PDE4B

Indexed keywords

CILOMILAST; DIMETHYL SULFOXIDE; GAMMA INTERFERON; OXYGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PROTEIN SUBUNIT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROLIPRAM; SUPEROXIDE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENZYME INHIBITOR; FC RECEPTOR; ISOENZYME;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BIOLOGICAL MODEL; CELL STRAIN HL 60; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; TIME; UPREGULATION; CELL DIFFERENTIATION; CELL SIZE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION; GENETICS; METABOLISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CELL DIFFERENTIATION; CELL SIZE; DIMETHYL SULFOXIDE; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION; HL-60 CELLS; HUMANS; ISOENZYMES; NADPH OXIDASE; NEUTROPHILS; PHENOTYPE; RECEPTORS, IGG; SUPEROXIDES;

EID: 0036843180     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00141-8     Document Type: Article

References (46)

1. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65:2000;1-52.
2. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs. 59:2000;193-212.
3. Torphy T.J., De Wolf W.E. Jr., Grenn D.W., Livi G.P. Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl. 43:1993;51-71.
4. Engels P., Fichtel K., Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:1994;291-295.
5. Souness J.E., Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signal. 9:1997;227-236.
6. Conti M., Swinnen J.V., Tsikalas K.E., Jin S.L. Structure and regulation of the rat high-affinity cyclic AMP phosphodiesterases. A family of closely related enzymes. Adv. Second Messenger Protein Phosphoryl. Res. 25:1992;87-99.
7. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
8. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 44:1998;225-342.
9. Tsafriri A., Chun S.Y., Zhang R., Hsueh A.J., Conti M. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Dev. Biol. 178:1996;393-402.
10. Pryzwansky K.B., Kidao S., Merricks E.P. Compartmentalization of PDE-4 and cAMP-dependent protein kinase in neutrophils and macrophages during phagocytosis. Cell Biochem. Biophys. 28:1998;251-275.
11. Doherty A.M. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr. Opin. Chem. Biol. 3:1999;466-473.
12. Essayan D.M. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 57:1999;965-973.
13. Escofier N., Boichot E., Germain N., Silva E.P.M., Martins M.A., Lagente V. Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung. Fundam. Clin. Pharmacol. 13:1999;96-101.
14. Nielson C.P., Vestal R.E., Sturm R.J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86:1990;801-808.
15. Wang J.P., Raung S.L., Huang L.J., Kuo S.C. Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils. Biochem. Pharmacol. 56:1998;1505-1514.
16. Barnette M.S., Manning C.D., Cieslinski L.B., Burman M., Christensen S.B., Torphy T.J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther. 273:1995;674-679.
17. Dent G., Poppe H., Egerland J., Marx D., Szelenyi I., Branscheid D.et al. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm. Pharmacol. Ther. 11:1998;13-21.
18. Segal A.W., Garcia R., Goldstone A.H., Cross A.R., Jones O.T. Cytochrome b-245 of neutrophils is also present in human monocytes, macrophages and eosinophils. Biochem. J. 196:1981;363-367.
19. ·(-)-generating oxidase from human blood monocytes: comparison to the neutrophil system. Blood. 60:1982;979-983.
20. Petreccia D.C., Nauseef W.M., Clark R.A. Respiratory burst of normal human eosinophils. J. Leukoc. Biol. 41:1987;283-288.
21. Niwa M., Kozawa O., Matsuno H., Kanamori Y., Hara A., Uematsu T. Tumor necrosis factor-alpha-mediated signal transduction in human neutrophils: involvement of sphingomyelin metabolites in the priming effect of TNF-alpha on the fMLP-stimulated superoxide production. Life Sci. 66:2000;245-256.
22. Burnham D.N., Tyagi S.R., Uhlinger D.J., Lambeth J.D. Diacylglycerol generation and phosphoinositide turnover in human neutrophils: effects of particulate versus soluble stimuli. Arch. Biochem. Biophys. 269:1989;345-353.
23. Tsunawaki S., Mizuno D., Kakinuma K., Kasahara M. An Fc-receptor activity of plasma membranes from guinea-pig peritoneal polymorphonuclear leucocytes. Biochem. J. 204:1982;625-634.
24. De Leo F.R., Renee J., Mc Cormick S., Nakamura M., Apicella M., Weiss J.P.et al. Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J. Clin. Invest. 101:1998;455-463.
25. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:1989;1045-1049.
26. Daniels I., Lindsay M.A., Keany C.L., Burden R.P., Fletcher J., Haynes A.P. Role of arachidonic acid and its metabolites in the priming of NADPH oxidase in human polymorphonuclear leukocytes by peritoneal dialysis effluent. Clin. Diagn. Lab. Immunol. 5:1998;683-689.
27. Robinson J.M., Badwey J.A., Karnowsky M.L., Karnowsky M.J. Release of superoxide and change in morphology by neutrophils in response to phorbol esters: antagonism by inhibitors of calcium-binding proteins. J. Cell Biol. 101:1985;1052-1058.
28. Becker E.L., Sigman M., Oliver J.M. Superoxide production induced in rabbit polymorphonuclear leukocytes by synthetic chemotactic peptides and A23187. Am. J. Pathol. 95:1979;81-97.
29. Christensen S.B., Guider A.M., Forster C.J., Gleason J.G., Bender P.E., Karpinski J.M.et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem. 41:1998;821-835.
30. Holevinsky K.O., Nelson D.J. Simultaneous detection of free radical release and membrane current during phagocytosis. J. Biol. Chem. 270:1995;8328-8336.
31. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
32. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
33. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology. 24:1992;145-149.
34. Hulett M.D., Hogarth P.M. Molecular basis of Fc receptor function. Adv. Immunol. 57:1994;1-127.
35. Van De Winkel J.G.J., Anderson C.L. Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 49:1991;511-524.
36. Allen J.M., Seed B. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science. 243:1989;378-381.
37. Trayner I.D., Bustorff T., Etches A.E., Mufti G.J., Foss Y., Farzaneh F. Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha 1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. Leuk. Res. 22:1998;537-547.
38. Satriano J., Schlondorff D. Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J. Clin. Invest. 94:1994;1629-1636.
39. Takei K., Tokuyama K., Kato M., Morikawa A. Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages. Pharmacology. 57:1998;1-7.
40. Mahomed A.G., Theron A.J., Anderson R., Feldman C. Anti-oxidative effects of theophylline on human neutrophils involve cyclic nucleotides and protein kinase A. Inflammation. 22:1998;545-557.
41. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297:2001;267-279.
42. Bengis-Garber C., Gruener N. Protein kinase A downregulates the phosphorylation of p47phox in human neutrophils: a possible pathway for inhibition of the respiratory burst. Cell. Signal. 8:1996;291-296.
43. Wang P., Wu P., Ohleth K.M., Egan R.W., Billah M.M. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol. 56:1999;170-174.
44. Manning C.D., Burman M., Chritensen S.B., Cieslinski L.B., Essayan D.M., Grous M.et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol. 128:1999;1393-1398.
45. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 157:1998;351-370.
46. Horowski R., Sastre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Ther. Res. 38:1985;23-29.